JP2016505065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505065A5 JP2016505065A5 JP2015554265A JP2015554265A JP2016505065A5 JP 2016505065 A5 JP2016505065 A5 JP 2016505065A5 JP 2015554265 A JP2015554265 A JP 2015554265A JP 2015554265 A JP2015554265 A JP 2015554265A JP 2016505065 A5 JP2016505065 A5 JP 2016505065A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- peptide
- natriuretic peptide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 12
- 102000004571 Natriuretic peptide Human genes 0.000 claims 12
- 239000000692 natriuretic peptide Substances 0.000 claims 12
- 230000002526 effect on cardiovascular system Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 101710158332 Diuretic hormone Proteins 0.000 claims 4
- 101710204261 Diuretic hormone class 2 Proteins 0.000 claims 4
- 108010001957 Ularitide Proteins 0.000 claims 4
- 102400001279 Urodilatin Human genes 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 4
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 claims 4
- 229940124549 vasodilator Drugs 0.000 claims 4
- 239000003071 vasodilator agent Substances 0.000 claims 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 claims 2
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 claims 2
- 108010050286 Dendroaspis natriuretic peptide Proteins 0.000 claims 2
- 102400000686 Endothelin-1 Human genes 0.000 claims 2
- 101800004490 Endothelin-1 Proteins 0.000 claims 2
- 102000000802 Galectin 3 Human genes 0.000 claims 2
- 108010001517 Galectin 3 Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- -1 IL-1β Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000009635 nitrosylation Effects 0.000 claims 2
- 230000000304 vasodilatating effect Effects 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010064966 Myocardial oedema Diseases 0.000 claims 1
- 108090000103 Relaxin Proteins 0.000 claims 1
- 102000003743 Relaxin Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001267 nesiritide Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756692P | 2013-01-25 | 2013-01-25 | |
| US61/756,692 | 2013-01-25 | ||
| PCT/IB2014/000253 WO2014115033A2 (en) | 2013-01-25 | 2014-01-24 | Methods of treating cardiovascular indications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016505065A JP2016505065A (ja) | 2016-02-18 |
| JP2016505065A5 true JP2016505065A5 (enExample) | 2016-12-01 |
Family
ID=50382492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554265A Pending JP2016505065A (ja) | 2013-01-25 | 2014-01-24 | 心血管症候の治療方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140213520A1 (enExample) |
| EP (1) | EP2948165A2 (enExample) |
| JP (1) | JP2016505065A (enExample) |
| KR (1) | KR20150108903A (enExample) |
| CN (1) | CN105025918A (enExample) |
| AP (1) | AP2015008624A0 (enExample) |
| AU (1) | AU2014208851B2 (enExample) |
| BR (1) | BR112015017432A2 (enExample) |
| CA (1) | CA2898571A1 (enExample) |
| DO (1) | DOP2015000175A (enExample) |
| EA (1) | EA201500765A1 (enExample) |
| IL (1) | IL239909A0 (enExample) |
| MX (1) | MX2015009606A (enExample) |
| NZ (1) | NZ710246A (enExample) |
| PH (1) | PH12015501559A1 (enExample) |
| SG (1) | SG11201505492XA (enExample) |
| TN (1) | TN2015000315A1 (enExample) |
| TW (1) | TW201442722A (enExample) |
| WO (1) | WO2014115033A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184248A1 (en) * | 2014-05-30 | 2015-12-03 | Concert Pharmaceuticals, Inc. | Methods of treating fibrotic diseases |
| CN105617360B (zh) * | 2015-12-04 | 2018-12-21 | 中国农业大学 | C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用 |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN110278941B (zh) * | 2019-07-11 | 2021-05-28 | 西安国际医学中心有限公司 | 一种含有钠尿肽的离体心脏保护液 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346953A1 (de) | 1983-12-24 | 1985-08-14 | Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg | Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung |
| US5449751A (en) | 1987-03-02 | 1995-09-12 | Pharma Bissendorf Peptide Gmbh | Cardiodilatin fragment, process for preparing same and use thereof |
| US5461142A (en) | 1987-11-07 | 1995-10-24 | Pharma Bissendorf Peptide Gmbh | Phosphorylated derivatives of cardiodilatin/ANF peptides |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| DE4216133A1 (de) | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
| ES2188665T3 (es) | 1994-06-02 | 2003-07-01 | Forssmann Wolf Georg | Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. |
| DE19951471A1 (de) | 1999-10-26 | 2001-05-03 | Forssmann Wolf Georg | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| NZ525389A (en) * | 2000-10-04 | 2009-04-30 | Molecular Medicine Res Inst | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20050113286A1 (en) * | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| WO2006110743A1 (en) * | 2005-04-07 | 2006-10-19 | Cardiopep Pharma Gmbh | Use of natriuretic peptide for treating heart failure |
| US8293711B2 (en) * | 2007-09-11 | 2012-10-23 | Pharis Biotech Gmbh | Use of natriuretic peptides for treating angioedema syndromes |
| WO2009086126A2 (en) * | 2007-12-21 | 2009-07-09 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| CN104815319A (zh) * | 2008-05-16 | 2015-08-05 | 科尔泰拉公司 | 治疗慢性心力衰竭的方法 |
| WO2010048308A2 (en) * | 2008-10-24 | 2010-04-29 | Deborah Dickey | Natriuretic polypeptides |
| JP2010116325A (ja) * | 2008-11-11 | 2010-05-27 | Institute For Protein Science Co Ltd | Ｓｉｒｓ患者を救命するためのペプチド組成物 |
| US20110014180A1 (en) * | 2009-07-16 | 2011-01-20 | Masafumi Koide | Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
| UY32902A (es) * | 2009-09-25 | 2011-02-28 | Alcon Res Ltd | Nuevos agonistas de npr-b |
| US8551938B2 (en) * | 2009-09-25 | 2013-10-08 | Alcon Research, Ltd. | NPR-B agonists |
| US20130197188A1 (en) * | 2010-03-15 | 2013-08-01 | Wolf-Georg Forssmann | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound |
| US20120052097A1 (en) * | 2010-08-20 | 2012-03-01 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
-
2014
- 2014-01-24 WO PCT/IB2014/000253 patent/WO2014115033A2/en not_active Ceased
- 2014-01-24 TW TW103102790A patent/TW201442722A/zh unknown
- 2014-01-24 SG SG11201505492XA patent/SG11201505492XA/en unknown
- 2014-01-24 EP EP14712761.7A patent/EP2948165A2/en not_active Withdrawn
- 2014-01-24 US US14/163,273 patent/US20140213520A1/en not_active Abandoned
- 2014-01-24 CA CA2898571A patent/CA2898571A1/en not_active Abandoned
- 2014-01-24 BR BR112015017432A patent/BR112015017432A2/pt not_active IP Right Cessation
- 2014-01-24 NZ NZ710246A patent/NZ710246A/en not_active IP Right Cessation
- 2014-01-24 AP AP2015008624A patent/AP2015008624A0/xx unknown
- 2014-01-24 AU AU2014208851A patent/AU2014208851B2/en not_active Ceased
- 2014-01-24 CN CN201480013163.1A patent/CN105025918A/zh active Pending
- 2014-01-24 JP JP2015554265A patent/JP2016505065A/ja active Pending
- 2014-01-24 MX MX2015009606A patent/MX2015009606A/es unknown
- 2014-01-24 KR KR1020157022509A patent/KR20150108903A/ko not_active Withdrawn
- 2014-01-24 EA EA201500765A patent/EA201500765A1/ru unknown
- 2014-01-24 US US14/163,130 patent/US20140213519A1/en not_active Abandoned
-
2015
- 2015-07-13 IL IL239909A patent/IL239909A0/en unknown
- 2015-07-13 PH PH12015501559A patent/PH12015501559A1/en unknown
- 2015-07-23 TN TN2015000315A patent/TN2015000315A1/en unknown
- 2015-07-24 DO DO2015000175A patent/DOP2015000175A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Natriuretic peptides and cardiometabolic health | |
| Madamanchi et al. | Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure | |
| CN103212063B (zh) | 用松弛素治疗与急性心力衰竭相关的呼吸困难 | |
| JP2017061453A5 (enExample) | ||
| Del Ry et al. | Recent advances on natriuretic peptide system: new promising therapeutic targets for the treatment of heart failure | |
| Del Ry et al. | Natriuretic peptide system and the heart | |
| JP2016505065A5 (enExample) | ||
| JP2011522824A5 (enExample) | ||
| Szczepanska-Sadowska et al. | Vasopressin and related peptides; potential value in diagnosis, prognosis and treatment of clinical disorders | |
| Kalra et al. | The role of C-type natriuretic peptide in cardiovascular medicine | |
| JP2016512205A5 (enExample) | ||
| Rocha et al. | Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials | |
| Zamani et al. | Novel vasodilators in heart failure | |
| Fu et al. | Therapeutic progress and knowledge basis on the natriuretic peptide system in heart failure | |
| RU2017142779A (ru) | Перенос гена cmlck | |
| Skvortsov et al. | Therapy of High Risk Patients After Decompensation of Heart Failure Under NT-proBNP Control. Main Results | |
| Luo et al. | Effects of liraglutide on ANP secretion and cardiac dynamics | |
| Pemberton et al. | Cardiac natriuretic peptides | |
| Bekele | Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure | |
| Toma et al. | Evolution of arterial hypertension in patients with hepatitis C virus cirrhosis after antiviral treatment | |
| Sasaoka et al. | Low dose carperitide (alpha-hANP) administration is effective for preventing worsening renal function (WRF) and long-term renal protection | |
| Vedavathi | NT-proBNP as a Diagnostic Marker in CCF | |
| Rohit et al. | To Evaluate the Efficacy of Heart Failure Reversal Therapy Using NT-Probnp Levels in Patients with Chronic Heart Failure | |
| Yip | B-type natriuretic peptide: a treatment, not a diagnostic marker | |
| Abdulla et al. | Cardiac and circulatory problems |